-+ 0.00%
-+ 0.00%
-+ 0.00%

Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M

Benzinga·05/26/2026 20:50:07
Listen to the news

Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(3.65) per share which missed the analyst consensus estimate of $(0.68) by 444.78 percent as R&D spend Jumps to $70.9M.